Bio-Path Holdings (BPTH)
(Delayed Data from NSDQ)
$0.89 USD
-0.07 (-7.26%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $0.90 +0.01 (1.01%) 6:54 PM ET
4-Sell of 5 4
F Value A Growth C Momentum C VGM
Brokerage Reports
0 items in cart
Bio-Path Holdings, Inc. [BPTH]
Reports for Purchase
Showing records 1 - 20 ( 126 total )
Company: Bio-Path Holdings, Inc.
Industry: Medical - Drugs
Initial Prexigebersen-A Solid Tumor Data, Updates Phase 2 AML Program
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Bio-Path Holdings, Inc.
Industry: Medical - Drugs
2Q24: Clinical Trials Progressing, No Material Updates
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Bio-Path Holdings, Inc.
Industry: Medical - Drugs
Company: Bio-Path Holdings, Inc.
Industry: Medical - Drugs
Updates Cancer Clinical Progress, to Begin Preclinical Obesity Studies
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Bio-Path Holdings, Inc.
Industry: Medical - Drugs
Company: Bio-Path Holdings, Inc.
Industry: Medical - Drugs
Updated PL Model, Same Positive Phase 2 AML Data At EHA As At ASCO
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Bio-Path Holdings, Inc.
Industry: Medical - Drugs
Solid AML Efficacy With Prexigebersen Plus Decitabine And Venetoclax
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Bio-Path Holdings, Inc.
Industry: Medical - Drugs
1Q24: Clinical Trials Progressing, No Material Updates
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Bio-Path Holdings, Inc.
Industry: Medical - Drugs
BP1002 Phase 1/1b AML Trial Second Dose Cohort Successfully Completed
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Bio-Path Holdings, Inc.
Industry: Medical - Drugs
Business Update Includes Developing Prexigebersen For Obesity
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Bio-Path Holdings, Inc.
Industry: Medical - Drugs
Company: Bio-Path Holdings, Inc.
Industry: Medical - Drugs
Safely Completes BP1002 Phase 1/1b Dose Cohort 1 in Rel/Ref AML
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Bio-Path Holdings, Inc.
Industry: Medical - Drugs
Company: Bio-Path Holdings, Inc.
Industry: Medical - Drugs
3Q23: Prex AML Cohorts 1 2 Show Positive Data, Prex-A Data In Early 2024
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Bio-Path Holdings, Inc.
Industry: Medical - Drugs
2Q23: Prex AML Cohorts 1 2 Yield Positive Data, Prex-A Cohort 1 Finished
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Bio-Path Holdings, Inc.
Industry: Medical - Drugs
Company: Bio-Path Holdings, Inc.
Industry: Medical - Drugs
Company: Bio-Path Holdings, Inc.
Industry: Medical - Drugs
Prex AML Cohorts 1 2 Yield Positive Data, Prex-A Cohort 1 Finished
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Bio-Path Holdings, Inc.
Industry: Medical - Drugs
Company: Bio-Path Holdings, Inc.
Industry: Medical - Drugs
1Q23: Catalyst Rich 2023, Manufacturing Challenges Are In The Past
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J